FocalTherics Prices $40M ADS Offering at $4.75, a 7% Discount
FOCL has more than doubled off its 52-week low of $1.26.
Summary
FocalTherics priced its public offering of 8.425 million ADSs at $4.75 each, a 7% discount to the last close of $5.10, with each ADS representing one ordinary share. The deal raises roughly $40 million in gross proceeds, and underwriters have a 30-day option to purchase up to an additional 1.3 million ADSs at the public offering price. This follows the preliminary Q2 HIFU revenue beat reported earlier today, which showed 34-39% growth. The discount and dilution are material for a $228 million market cap company, but the raise strengthens the balance sheet amid commercial expansion. Watch for use-of-proceeds details in the final prospectus.
At the time of this announcement, FOCL was trading at $5.10 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $227.9M. The 52-week trading range was $1.26 to $6.40. This news item was assessed with neutral market sentiment and an importance score of 8 out of 10. Source: Reuters.